Vizmanos José L, Novo Francisco J, Román José P, Baxter E Joanna, Lahortiga Idoya, Larráyoz María J, Odero María D, Giraldo Pilar, Calasanz María J, Cross Nicholas C P
Department of Genetics, University of Navarra, Pamplona, Spain.
Cancer Res. 2004 Apr 15;64(8):2673-6. doi: 10.1158/0008-5472.can-04-0144.
We describe a new PDGFRB fusion associated with a t(5;14)(q33;q24) in a patient with a longstanding chronic myeloproliferative disorder with eosinophilia. After confirmation of PDGFRB involvement and definition of the chromosome 14 breakpoint by fluorescence in situ hybridization, candidate partner genes were selected on the basis of the presence of predicted oligomerization domains believed to be an essential feature of tyrosine kinase fusion proteins. We demonstrate that the t(5;14) fuses PDGFRB to NIN, a gene encoding a centrosomal protein with CEP110-like function. After treatment with imatinib, the patient achieved hematological and cytogenetical remission, but NIN-PDGFRB mRNA remained detectable by reverse transcription-PCR.
我们描述了一名患有长期嗜酸性粒细胞增多慢性骨髓增殖性疾病的患者中,一种与t(5;14)(q33;q24)相关的新的血小板衍生生长因子受体β(PDGFRB)融合。通过荧光原位杂交确认PDGFRB受累并确定14号染色体断点后,基于预测的寡聚化结构域的存在选择候选伙伴基因,这些结构域被认为是酪氨酸激酶融合蛋白的一个基本特征。我们证明t(5;14)将PDGFRB与NIN融合,NIN是一个编码具有CEP110样功能的中心体蛋白的基因。用伊马替尼治疗后,患者实现了血液学和细胞遗传学缓解,但通过逆转录聚合酶链反应仍可检测到NIN-PDGFRB mRNA。